ICON Public Company (ICLR) Q2 2024 earnings summary

Executive summary

• Achieved strong Q2 2024 results with revenue growth, margin expansion, robust cash flow, and new business wins across segments.

• Net business wins and backlog grew, with backlog at $23.8 billion, up 9.9% year-over-year.

• Benefited from positive CRO market dynamics, stabilization in biotech, and strength in large pharma, including new strategic partnerships.

• COVID vaccine trial delays impacted 2024 revenue, but studies are expected to enroll mainly in 2025.

• Strengthened balance sheet through successful debt refinancing and reduced net debt.

Financial highlights

• Q2 2024 revenue was $2,120.2 million, up 4.9% year-over-year (5.3% constant currency).

• Adjusted EBITDA was $450.4 million (21.2% margin), up 8.7% year-over-year.

• Adjusted EPS was $3.75, up 20.6% year-over-year.

• Free cash flow for Q2 was $182.4 million; trailing twelve months free cash flow was $1,182.1 million.

• Backlog increased to $23.8 billion, up 9.9% year-over-year.

Outlook and guidance

• 2024 revenue guidance updated to $8,450–$8,550 million, up 4.1%–5.3% year-over-year.

• Full-year adjusted EPS guidance raised to $15.00–$15.20, up 17.3%–18.8% year-over-year.

• Adjusted EBITDA margin guidance increased to 21.7% at midpoint, up 80 bps year-over-year.

• Free cash flow target for 2024 is ~$1.1 billion.

• Guidance reflects COVID delays, FX headwinds, and assumes a 16.5% effective tax rate.